EQL Pharma AB (OSTO:EQL) EV-to-FCF: -27.50 (As of Jul. 03, 2026)


OSTO:EQL EQL Pharma AB OSTO:EQL
42 GF Score
Price kr23.15
! 4 Warning Signs
View Full Analysis

What is EQL Pharma AB EV-to-FCF?

EQL Pharma AB OSTO:EQL -2.32% 42 EV-to-FCF is -27.50 as of Jul. 03, 2026. GuruFocus rates OSTO:EQL with a GF Score™ of 42/100. The stock has 4 warning signs investors should review. Among 562 Drug Manufacturers companies, EQL Pharma AB ranks worse than 177935.77% on this metric.

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, EQL Pharma AB's Enterprise Value is kr1,082.0 Mil. EQL Pharma AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was kr-39.4 Mil. Therefore, EQL Pharma AB's EV-to-FCF for today is -27.50.

The historical rank and industry rank for EQL Pharma AB's EV-to-FCF or its related term are showing as below:

OSTO:EQL' s EV-to-FCF Range Over the Past 10 Years
Min: -54.67   Med: -15.67   Max: -6.69
Current: -27.83

During the past 13 years, the highest EV-to-FCF of EQL Pharma AB was -6.69. The lowest was -54.67. And the median was -15.67.

OSTO:EQL's EV-to-FCF is ranked worse than
100% of 562 companies
in the Drug Manufacturers industry
Industry Median: 20.525 vs OSTO:EQL: -27.83

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-07-03), EQL Pharma AB's stock price is kr23.15. EQL Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.420. Therefore, EQL Pharma AB's PE Ratio (TTM) for today is 55.12.


EQL Pharma AB  (OSTO:EQL) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

EQL Pharma AB's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=23.15/0.420
=55.12

EQL Pharma AB's share price for today is kr23.15.
EQL Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.420.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


EQL Pharma AB EV-to-FCF Related Terms


EQL Pharma AB EV-to-FCF Historical Data

* Premium members only.

The historical data trend for EQL Pharma AB's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EQL Pharma AB EV-to-FCF Chart

EQL Pharma AB Annual Data
Trend Dec16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -9.01 -51.56

EQL Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.01 -11.18 -8.54 -7.87 -51.56

OSTO:EQL vs ZTS, UTHR: EV-to-FCF Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, EQL Pharma AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EQL Pharma AB EV-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, EQL Pharma AB's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where EQL Pharma AB's EV-to-FCF falls into.


OSTO:EQL
42GF Score
EQL Pharma AB OSTO:EQL
EV-to-FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

EQL Pharma AB EV-to-FCF Calculation

EQL Pharma AB's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1082.001/-39.352
=-27.50

EQL Pharma AB's current Enterprise Value is kr1,082.0 Mil.
EQL Pharma AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-39.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-FCF →
What does a EV-to-FCF of -27.50 mean?
EQL Pharma AB (OSTO:EQL) has a EV-to-FCF of -27.50 as of Jul. 03, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on EQL Pharma AB and its competitors. According to the industry distribution chart, EQL Pharma AB ranks #999999 out of 562 companies in the Drug Manufacturers industry.
Is EQL Pharma AB's EV-to-FCF too high?
EQL Pharma AB's current EV-to-FCF is -27.50. Based on the distribution chart, EQL Pharma AB ranks #999999 out of 562 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, EQL Pharma AB has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does EQL Pharma AB's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, EQL Pharma AB ranks #999999 out of 562 companies for EV-to-FCF. This places EQL Pharma AB in the lower half of its industry. The industry median EV-to-FCF is 20.53. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.53, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on EQL Pharma AB and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EQL Pharma AB's current EV-to-FCF is -27.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EQL Pharma AB stock overvalued right now?
EQL Pharma AB (OSTO:EQL) has a current EV-to-FCF of -27.50. The current EV-to-FCF is -27.50. EQL Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For EQL Pharma AB (OSTO:EQL), the current EV-to-FCF is -27.50 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

EQL Pharma AB Business Description

Other Exchanges 7JK:Germany
Address Stortorget 1, 3rd Floor, Lund, SWE, 222 23
EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.
42GF Score

Get the complete analysis for OSTO:EQL

EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr23.15
Price